Share on StockTwits

Auxilium Pharmaceuticals (NASDAQ:AUXL) will be issuing its Q214 quarterly earnings data on Thursday, August 7th. Analysts expect the company to announce earnings of $1.64 per share and revenue of $482.80 million for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Shares of Auxilium Pharmaceuticals (NASDAQ:AUXL) opened at 19.34 on Wednesday. Auxilium Pharmaceuticals has a one year low of $16.36 and a one year high of $32.89. The stock’s 50-day moving average is $20.10 and its 200-day moving average is $24.03. The company’s market cap is $971.5 million.

A number of research firms have recently commented on AUXL. Analysts at Aegis initiated coverage on shares of Auxilium Pharmaceuticals in a research note on Thursday, June 26th. They set a “buy” rating and a $37.00 price target on the stock. On the ratings front, analysts at MKM Partners upgraded shares of Auxilium Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note on Wednesday, May 28th. They now have a $26.00 price target on the stock. They noted that the move was a valuation call. Finally, analysts at TheStreet downgraded shares of Auxilium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd. Four research analysts have rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company. Auxilium Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $26.79.

Auxilium Pharmaceuticals, Inc is a specialty biopharmaceutical company focuses on developing and marketing products to predominantly specialist audiences.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.